On September 30, 2026, Liquidia Corporation issued an update regarding ongoing litigation with United Therapeutics Corporation (UTHR) concerning U.S. Patent No. 11,826,327 and the company's lead product, YUTREPIA (treprostinil) inhalation powder.
The U.S. District Court for the District of Delaware ruled that claims 1 and 14 of the '327 patent are valid and infringed by Liquidia. These claims generally cover the treatment of pulmonary hypertension with interstitial lung disease (PH-ILD) patients using inhaled treprostinil, including dry powder formulations. The remaining claims asserted against Liquidia were found to be invalid.
United Therapeutics has requested injunctive relief to restrict YUTREPIA's availability on the market. The parties have been directed to submit a form of judgment to the Court within one week to specify proposed remedies for the infringement.
Liquidia's CEO, Roger Jeffs, stated the company respectfully disagrees with the decision regarding claims 1 and 14 and is prepared to pursue appellate options. The company also noted its intention to submit a supplement to YUTREPIA's New Drug Application to the FDA to remove the PH-ILD indication from the label.
Given the variables involved, including potential appeals, the company stated it is not possible to reasonably estimate the range of potential outcomes or financial exposure at this time. Potential remedies could range from removing the PH-ILD indication from the label to broader restrictions on product availability.
